Trulicity vs Ozempic: the head-to-head trial result

Trulicity and Ozempic are close cousins — both once-weekly GLP-1 injections for type-2 diabetes — and, helpfully, they were tested against each other in a proper randomized trial. The result is clear: dose for dose, Ozempic (semaglutide) did more. Here’s what the trial actually showed, and where Trulicity still fits.

Two once-weekly GLP-1 drugs

Both Trulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 receptor agonists — they mimic the same gut hormone to lower blood sugar and appetite — and both are taken as a once-weekly injection. They’re the same class doing the same job; the question SUSTAIN-7 answered is which one does it more effectively.

The head-to-head: SUSTAIN-7

SUSTAIN-7 was a 40-week trial in 1,201 adults with type-2 diabetes that paired the drugs at matched doses: semaglutide 0.5 mg versus dulaglutide 0.75 mg, and semaglutide 1.0 mg versus dulaglutide 1.5 mg.^[1] Semaglutide lowered HbA1c more in both pairs — 1.5 vs 1.1 pointsat the lower doses and 1.8 vs 1.4 points at the higher doses.^[1] And it produced clearly more weight loss.

Where Trulicity still fits

Semaglutide winning the efficacy contest doesn’t make dulaglutide a bad drug — it’s a well-established, effective once-weekly option, and efficacy is only one input. Real-world choice between two GLP-1 drugs also turns on how a given person tolerates each (GI side effects vary individually), injection-device preference, cost, and which one a particular insurance plan covers. For some patients those factors matter more than the difference between 6.5 and 3.0 kg.

The honest verdict

Head-to-head, Ozempic outperformed Trulicity on both blood sugar and weight at matched doses.^[1]If raw efficacy is the deciding factor, semaglutide is the stronger choice. But dulaglutide remains a solid, simpler-to-use option, and tolerability, cost and coverage legitimately swing the decision for many people. Compare the whole class in our GLP-1 comparison tool, and find the routes to a prescription in our GLP-1 provider guide.